As the Trends Journal reported on 19 January in our article, “COVID-19 VACCINES: TRACKING ADVERSE HEALTH EFFECTS,” the CDC’s National Center for Immunization and Respiratory Diseases confirmed that severe allergic reactions to the new vaccines were ten times more likely than from the flu vaccine.
The article quoted the website Medical News Today:
“Data collected so far showed some 2.7 percent of those who received a COVID-19 vaccine reported a ‘Health Impact Event,’ which means a person is ‘Unable to perform normal daily activities, unable to work and/or required care from a doctor or health care professional.’”
On 2 February, we published additional data in our article, “STATS, SIDE EFFECTS & DEATHS”:
An article published by Science magazine on 1 January stated: “Severe allergy-like reactions in people who received the COVID-19 vaccine produced by Pfizer and BioNTech in December 2020 may be due to a compound in the packaging of the messenger RNA (mRNA) that forms the vaccine’s main ingredient, scientists say.”
Now, in addition to questions about the never-before administered mRNA vaccines, which were rushed into circulation through the FDA’s Emergency Use Authorization, a new question has been raised.
As reported last Friday in the article by SF Gate, “Pfizer Plant Boosting Vaccines Has Repeat Quality Offenses,” it turns out the large plant that is currently ramping up millions of doses of vaccines has been previously cited for multiple health violations.
According to the article,
“Food and Drug Administration inspectors visited the McPherson, Kansas, plant at the end of 2019 into January 2020, according to an inspection report obtained by Bloomberg via a Freedom of Information request. They found the drug giant released medications for sale after failing to thoroughly review quality issues that arose in routine testing, the report shows.”
The report revealed bacteria and mold in areas required to be sterile, and it wasn’t the first time. The same health issue was found by inspectors during earlier visits to the pharmaceutical plant. In 2017, the FDA sent Pfizer a warning letter acknowledging “significant violations of current good manufacturing rules.” Drugs were discovered contaminated.
The violations continued:
“During the FDA’s visit in 2018, it found that Pfizer had turned up mold in the factory stemming from product residue on the machinery. The company blamed it on inadequate cleaning but then found residue in the same area again months later. FDA inspectors found at their 2020 inspection that Pfizer ‘continues to recover bacterial and/or mold isolates from critical zones.’”
A Pfizer spokesperson, Sharon Castillo, released a statement that read, “We place the utmost emphasis on patient safety and product quality at every step in our manufacturing processes.”
Pfizer has said it will be producing an additional 200 million doses by the end of May. These doses will be packaged and shipped from this Kansas facility.
Despite shorter safety trials and pressure to get vaccines out as quickly as possible under Operation Warp Speed, the FDA issued a statement last Thursday that it “used all available tools and information to assess compliance with current good manufacturing practice requirements for each manufacturing site and included several conditions in the letter of authorization to ensure compliance.”
TRENDPOST: Despite legitimate concerns about the safety of the never-before administered mRNA vaccines, which were tested for only two months and released under the FDA’s Emergency Use Authorization, now, the added concerns of safety violations at a major Pfizer plant, President Biden’s “war” campaign against the coronavirus seems to be working.
According to the Wall Street Journal, on Saturday, 69 percent of Americans have either been vaccinated or plan to.
Last November, only 60 percent said they would definitely get jabbed. This increase is even greater among African-Americans where only 42 percent were planning on getting the shots last November compared to over 60 percent as of mid-February. The article writes that “to reach population-level immunity, and stop the spread of COVID-19… between 70 and 80 percent of the population must develop immunity, scientists say.”
